Healthcare
Live Price
Offline$1.71
+1.79% today
1Y Change
-46.06%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rapid Micro Biosystems, Inc. (RPID) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $1.71 and down 46.1% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +19.7%, EPS growth of +2.8%, a dividend yield of 0.0%. What stands out right now is revenue +19.7%, EPS +2.8%, free cash flow +29.9% with operating margin -141.1% and ROIC -82.2%. Valuation is more restrained than many high-expectation growth names at price/sales 3.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RPID price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RPID
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RPID Max Drawdown
-64.53%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RPID and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$23.2M
+35.6% YoY
FY Net Income
-$73.5M
-20.9% YoY
Free Cash Flow
-$58.2M
+10.9% YoY
Revenue Growth
+19.7%
EPS Growth
+2.8%
Gross Margin
17.4%
Net Margin
-140.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 34M | 28M | 23M | 17M | 23M |
| Gross Profit | 8M | -109K | -5M | -9M | -8M |
| Operating Income | -47M | -50M | -57M | -63M | -47M |
| EBITDA | -44M | -47M | -53M | -60M | -46M |
| Net Income | -47M | -47M | -52M | -61M | -74M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20M | 17M | 24M | 27M | 178M |
| Total Assets | 75M | 98M | 143M | 191M | 241M |
| Total Liabilities | 42M | 23M | 25M | 26M | 20M |
| Shareholder Equity | 33M | 75M | 118M | 164M | 221M |
| Total Debt | 24M | 6M | 7M | 8M | 0 |
| Net Debt | 4M | -11M | -17M | -19M | -178M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
55M
+6.1% YoY
Capital Expenditures
3M
+52.3% YoY
Free Cash Flow
58M
+10.9% YoY
Key ratios
Gross Margin
17.4%
Operating Margin
-141.1%
Net Margin
-140.3%
ROE
-95.4%
Debt / Equity
0.72x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.